Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer
Risk of death was reduced by 37% (HR=0.63) in patients treated with elraglusib/GnP
Data featured as an oral presentation at the ASCO Annual Meeting
Company plans to engage with FDA in the second half of 2025 to align on a path towards product registration
Company to host KOL event today at 6:30 pm CDT to discuss 1801 Part 3B results
CHICAGO and FORT WORTH, Texas, May 31, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) ('Actuate' or the 'Company'), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today presented topline results from the Phase 2 (Actuate-1801 Part 3B) trial of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) at the American Society of Clinical Oncology (ASCO) Annual Meeting.
Abstract Title: Preliminary results from the randomized phase 2 study (1801 Part 3B) of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) versus GnP alone in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).Abstract Number: 4006Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryPresenter: Devalingam Mahalingam, MD, PhDOral Presentation Date and Time: Saturday, May 31, 2025, 4:48 PM CDT
The trial met its primary endpoint of improved median overall survival. Median overall survival (mOS) increased by almost three months (10.1 months vs 7.2 months, HR=0.63, log-rank p=0.01) with a 37% reduction in the risk of death and strong statistical significance, representing a clinically meaningful advance in the potential treatment of mPDAC. Patients receiving elraglusib with GnP achieved a 12-month survival rate in 44.1% of patients treated—double that of GnP alone (22.3%).
Dr. Deva Mahalingam, MD, PhD, Northwestern University Feinberg School of Medicine, and lead principal investigator of the 1801 Part 3B trial commented, 'Pancreatic cancer continues to represent one of the highest unmet medical needs with no major treatment advances in recent years, bar some molecular targets in small subsets of patients. New mechanisms of action are urgently needed. The addition of elraglusib to the existing chemotherapy backbone of gemcitabine and nab-paclitaxel is promising and may represent a meaningful therapeutic advance for patients with pancreatic cancer.'
Daniel Schmitt, President & Chief Executive Officer of Actuate added, 'We significantly improved mOS, cut the risk of death by 37%, and doubled the 12-month survival rate. Combined with a manageable safety profile and strong emerging mechanistic insights, these results reinforce the transformative potential of our GSK-3β inhibitor program. Based on the clear clinical benefit and well-tolerated safety profile, we intend to engage with the FDA and EMA in the second half of this year to align on a path to registration. We believe this enables us to move rapidly towards commercialization and delivery of this first-in-class therapy to patients with an urgent unmet need.'
Efficacy
Figure 1 below depicts the Kaplan-Meier estimate for mOS (10.1 months vs 7.2 months, HR=0.63, log-rank p=0.01) with a 37% reduction in the risk of death, displaying a clear clinical survival benefit for patients treated in the elraglusib/GnP combination arm vs GnP alone arm.
Actuate-1801 Part 3B: Kaplan-Meier Estimate for mOS as of March 27, 2025 (Topline data cut-off).In addition to the improved mOS and one-year survival rate, a continued survival benefit was also observed at eighteen and twenty-four months (survival rates of 19.7% vs 4.4% and 13.8% vs 0% in the elraglusib/GnP combination arm vs the GnP arm, respectively).
The elraglusib/GnP combination treatment also resulted in numerically improved overall response rates (29.0% in the elraglusib/GnP combination arm vs 21.8% in the GnP arm) and improvements in median progression-free survival and median duration of response of 5.6 months vs 5.1 months, and 5.5 months vs 4.0 months in the elraglusib/GnP combination arms vs GnP arms, respectively.
Safety and Biomarker Findings
The trial also met its primary safety endpoint. Treatment-emergent adverse events (TEAEs) and Serious Adverse Events (SAEs) in the elraglusib/GnP combination arm were similar to those observed in the GnP arm, indicating a favorable risk-benefit profile for the elraglusib/GnP combination.
Treatment-related adverse events (TRAEs) were mostly Grade 1-2, with the most frequent TRAEs observed (in about two-thirds of patients) being transient visual impairments that were reversible and non-progressive
While Grade 3 or higher neutropenia was observed, similar rates of febrile neutropenia and sepsis were observed in both treatment arms.
Pre-dose cytokine analysis that suggested lower baseline levels of key immune modulators, including CCL3, IL-1α, IL-18, TGF-β, and TRAIL R3, were correlated with improved 1-year survival.
Increased CD8-positive and granzyme B-positive T cells, increased NK cells, and decreased myeloid-derived suppressor cells were observed in tumor biopsies only from elraglusib-treated patients. This exploratory result confirms elraglusib proposed immune modulating mechanism of action in patients with mPDAC.
KOL Event
Actuate will host a KOL event for the investment community today, May 31, 2025, at 6:30 PM CDT to review the data. The webinar will feature a fireside discussion moderated by Daniel Schmitt, President & Chief Executive Officer of Actuate, and will include four distinguished KOLs: Tanios Bekaii-Saab, MD, FACP, Mayo Clinic College of Medicine and Science; Devalingam Mahalingam, MD, Northwestern University Feinberg School of Medicine; Rachna Shroff, MD, MS, FASCO, University of Arizona Cancer Center; and Colin Weekes, MD, PhD, Massachusetts General Hospital.
Event Details:
Date and Time:
Saturday, May 31, 2025, at 6:30 pm CDT
Format:
In-person and via live webcast
Registration:
Click here
A replay of the event will be available on the Investor Relations section of the Actuate website.
About Actuate-1801 Part 3B Study
The Actuate-1801 Part 3B study (NCT03678883) is a randomized, controlled Phase 2 trial of elraglusib with GnP versus GnP alone in first-line mPDAC. The trial enrolled 286 mPDAC patients with no prior systemic treatment for metastatic disease, who were randomized 2:1 to the elraglusib treatment arm (elraglusib + GnP) or the control arm (GnP alone). Elraglusib is administered at a dose of 9.3 mg/kg by IV infusion on Day 1 of each week of a 28-day cycle. The primary endpoint for this study is median overall survival, with OS summarized throughout the study by estimates of 1-year survival. Secondary endpoints are DCR, ORR, PFS, and AE.Inhibition of GSK-3β may inhibit tumor growth and improve survival through several complimentary mechanisms that include enhancement of chemotherapy activity, activation of innate anti-tumor immunity, and regulation of gene expression, leading to alterations in tumor metabolism and Epithelial-to-Mesenchymal Transition (EMT).
About Actuate Therapeutics, Inc.
Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate's lead investigational drug, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy through the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and DNA Damage Response (DDR). Elraglusib may also mediate anti-tumor immunity through the regulation of multiple immune checkpoints and immune cell function. For additional information, please visit the Company's website at http://www.actuatetherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements about us, including our and other parties' clinical trials and development plans, and our industry. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'ongoing,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would,' or the negative of these terms or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All statements, other than statements related to present facts or current conditions or of historical facts, contained in this press release are forward-looking statements. Accordingly, these statements involve estimates, assumptions, substantial risks and uncertainties which could cause actual results to differ materially from those expressed in them, including but not limited to that preliminary and unpublished data may be subject to change and further interpretation following the availability of more data or following a more comprehensive review of the data and should not be relied upon as a final analysis; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities and within the medical community; clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes, results of prior preclinical studies and early clinical trials are not necessarily predictive of future results, and elraglusib may not achieve positive clinical results or favorable preclinical results, and we may not be able to make regulatory submissions or receive regulatory approval on a timely basis, if at all; that we may not successfully enroll additional patients or establish or advance plans for further development, including through conversations with the FDA or EMA and the standards such bodies may impose for such development; that elraglusib could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude regulatory approval, cause us to suspend or discontinue clinical trials or result in other negative consequences; our reliance on third parties to conduct our non-clinical studies and our clinical trials; our reliance on third-party licensors and ability to preserve and protect our intellectual property rights; that we face significant competition from other biotechnology and pharmaceutical companies; our ability to fund development activities, including because our financial condition raises substantial doubt as to our ability to continue as a going concern and we require additional capital to finance our operations beyond the second quarter of fiscal year 2025, and a failure to obtain this necessary capital in the near term on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations. In addition, any forward-looking statements are qualified in their entirety by reference to the factors discussed under the heading 'Item 1A. Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 13, 2025, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 15, 2025, and other filings with the SEC. Because the risk factors referred to above could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Unless legally required, we do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
Investor ContactMike MoyerManaging DirectorLifeSci Advisors, LLCmmoyer@lifesciadvisors.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ec493cba-bb28-4bc9-adae-263985865ae6
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
32 minutes ago
- Washington Post
What does Trump's tax law mean for your health insurance?
RFK Jr. has big plans for your food. Here are the facts. May 2, 2025
Yahoo
33 minutes ago
- Yahoo
Officials unveil high-powered contraption to fight dangerous issue at reservoirs: 'They tend to grow rampant'
Regional Water Authority personnel in Connecticut are doing their best Stanley Steemer impersonation. But instead of carpet cleaning, the team is using hot steam to battle invasive plants growing around reservoirs, according to WTNH News 8. "What I like about it is it seems to be controlling the seed bed as well as the plants that we're killing. The heat seems to be going into the surface layer of the soil," forester Casey Cordes said. The contraption looks like a carpet cleaner, with a hose connected to a hot steam machine. The workers are shown in footage shared by News 8, mushing up the invaders with water heated to 250 degrees Fahrenheit. The authority bought the equipment with a grant from the U.S. Forest Service, the TV station added. At issue are mugwort, stiltgrass, Japanese barberry, and other foreign plants that have taken root and spread quickly. The species have shallow root systems, so they don't hold soil well during heavy rains, which leads to erosion into reservoirs, per News 8. The troublesome weeds are also a problem for many homeowners. "They tend to grow rampant. They tend to take over areas in your yard or the edge of your yard. So, that gets the attention of a lot of homeowners," Cordes told the station. Columbia Climate School reported that the planet's overheating is aiding invasive species that take root in unwanted places. As conditions change in certain areas, native plants may not do as well as a new arrival, which can thrive and create an imbalance. The number of alien varieties, both plant and animal, is expected to jump 36% by 2050 as Earth continues to warm. An insect example is the emerald ash borer, which has destroyed 100 million trees in the United States since arriving from Asia. Which of these factors would most effectively motivate you to recycle old clothes and electronics? Giving me money back Letting me trade for new stuff Making it as easy as possible Keeping my stuff out of landfills Click your choice to see results and speak your mind. The ash borer is among thousands of invasive species in the country that caused more than $20 billion in damages and losses annually from 2010 to 2020. That was a sharp increase from the $2 billion in yearly costs during the 1960s, according to a study published by ScienceDirect. In Connecticut, the steam treatment also avoids the use of harmful herbicides, which can leach into reservoirs, per News 8. Steam is likely not a viable option for most homeowners battling unwanted plant life. But there are planet-friendly ways to encourage native ones to grow. Native species are a boon to pollinators and, in turn, about 35% of the food supply, according to the U.S. Department of Agriculture. Often, plants most people assume are weeds are actually native blooms that can be a part of a rewilded yard. Natural species require less work once established and don't need costly treatments and loads of water to maintain. A combination of steam and measures to encourage native plant growth could be a combination to tackle the unwanted and prolific outsiders plaguing reservoirs and backyards alike. "Deer are not going to eat them, insects are not going to eat them. So, they tend to run rampant in our forests," authority forester Joshua Tracy told News 8. Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.
Yahoo
34 minutes ago
- Yahoo
Opinion: How the Trump tax cut law will hurt the working class
Republican Sen. Lisa Murkowski of Alaska said it was 'agonizing' to vote for the tax cut bill President Trump signed on July 4. As details of the legislation come into focus, it's obvious why it might cause heartburn even for Republicans who passed it, with no Democratic votes. The One Big Beautiful Bill Act, as the law is clumsily known, will literally make the rich better off and the poor worse off. Some conservatives who want to pare the 'welfare state' may not care. But imposing austerity on millions of working-class voters is a stunning political risk for a party that is supposedly following President Trump's populist instincts. The law has two main elements. The first is a sweeping series of tax cuts and tax cut extensions that will generally benefit everybody but add trillions of dollars to the national debt. The second is a set of benefit cuts that are meant to reduce the overall cost of the bill. Those will hit working-class Americans and make the net effect of the bill punishing to them. The biggest part of the OBBBA is an extension of the tax cuts Trump signed into law in 2017. Those were due to expire at the end of this year. The OBBBA makes the current individual income tax rates permanent. Those are not 'tax cuts' per se, since tax rates will be the same in future years as they are in 2025. But the law does prevent what would have been a de facto tax hike if the 2017 rates expired and the higher 2016 rates went back into effect. The law also includes some new tax breaks, such as the elimination of tax on income from tips and overtime pay, up to certain limits. There's also a new tax break for some seniors and a much higher cap for deducting state and local taxes, which will mostly benefit wealthy homeowners who itemize deductions on their tax returns. The tax provisions generally benefit everybody, but the wealthy will gain the most. The average savings for all taxpayers will be about $2,900, compared with what the tax bill would have been if current rates expired, according to the Tax Policy Center. Those with incomes above $1 million would save nearly $60,000 on average. But the savings for workers with incomes below $30,000 would be less than $200 per year. Those provisions, at least, do no harm to most taxpayers. But the harm arrives when factoring in cuts to Medicaid, subsidies for people to buy health insurance through the Affordable Care Act, and food aid known as SNAP. The healthcare cutbacks will leave an additional 16 million people without coverage by 2034, according to the Congressional Budget Office. Cutbacks to the SNAP program could reduce or eliminate food aid going to 22 million families, according to the Urban Institute. Those changes will leave millions of Americans worse off. When accounting for the tax changes and benefit cuts combined, people in the lowest income quintile, with incomes below $13,500, will lose an average of $600 per year, according to the Yale Budget Lab. The next quintile will lose $65 per year. The healthcare and food aid cuts will have little impact on top earners, for obvious reasons. The top quintile will gain $6,500 in after-tax savings from all of the law's provisions, while the top 1% will net more than $30,000. This is what economists call a 'regressive' policy change because the economic burden falls more heavily on those with lower incomes. 'The bill has four overriding characteristics,' Howard Gleckman of the Tax Policy Center wrote recently. 'It is regressive, expensive, complicated, and it treats people who make roughly the same amount of money in very different ways.'Tax cut defenders often point out that the wealthy typically get the biggest tax cuts because they pay the most taxes in the first place. That's generally true. But the wealthy are a distinct minority, which means a regressive law such as the OBBBA dis-serves millions of voters, and possibly a majority of them. The bottom two income quintiles, for instance, include roughly 92 million taxpaying units, whether singles, married couples, or other designations. There are only 26 million taxpaying units in the top quintile. Maybe that's what Murkowski found so agonizing. 'Do I like this bill? No,' she told a reporter on July 2. 'I know in many parts of the country there are Americans that are not going to be advantaged by this bill.' Trump can point to working-class provisions such as the elimination of taxes on tip income and overtime pay, with limitations based on the type of work and the amount of income. Some workers will in fact benefit from those carve-outs. But tax analysts argue that favoring certain types of work in that manner violates the principle of 'horizontal equity,' the idea that similar incomes should be taxed in similar ways. To use the example of a restaurant, a waiter earning tip income would get a tax break that a cook paid hourly would not. That distorts the tax code, creates incentives to cheat, and generates legitimate grievances among the unlucky workers not gifted a tax break. The OBBBA is already unpopular, with 64% of Americans disapproving and just 35% approving, in one poll. The real vote will come in the 2026 midterm elections, when Americans will express whether they feel better off or worse off under unified Republican control of government. Getting Americans to like this law might be a more agonizing ideal than passing it. Rick Newman is a senior columnist for Yahoo Finance. Follow him on Bluesky and X: @rickjnewman. Click here for political news related to business and money policies that will shape tomorrow's stock prices.
